Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02318862 · ClinicalTrials.gov registry record · NA

Assessment of Esophageal Epithelium Integrity With Mucosal Impedance

A NA study, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT02318862 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02318862, a NA study, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.

Interventions

  • PROCEDURE Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2013-07
Est. Completion 2016-12
Phase NA

What the Registry Record Tells You About NCT02318862

The ClinicalTrials.gov registry entry for NCT02318862 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing is the first listed.

NCT02318862 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02318862 about?

NCT02318862 is a clinical study titled "Assessment of Esophageal Epithelium Integrity With Mucosal Impedance". Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for G...

What is the current status of trial NCT02318862?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2013-07. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02318862?

The interventions under investigation include: Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing (PROCEDURE).

Who is sponsoring clinical trial NCT02318862?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.